	Pre Utilidad Fiscal		Fecha
AbbVie	USD 4.38B	1.92B	2025-09
Acadia Pharmaceuticals	USD 26.32M	18.28M	2025-12
Agios Pharmaceuticals	USD -109.06M	5.62M	2025-12
ALKERMES	USD 100.74M	4.1M	2025-09
Alnylam Pharmaceuticals	USD 161.14M	77.83M	2025-12
Amgen	USD 3.92B	2.35B	2025-09
Biogen	USD 557.3M	186.7M	2025-09
BioMarin Pharmaceutical	USD -26.32M	324.19M	2025-09
Cytokinetics	USD -183.03M	123.15M	2025-12
Enanta Pharmaceuticals	USD -22.71M	95.08M	2024-12
Exelixis	USD 252.69M	275K	2025-12
Gilead Sciences	USD 3.64B	1.21B	2025-09
Halozyme Therapeutics	USD 218.96M	14.02M	2025-09
Incyte	USD 389.94M	92.37M	2025-12
Ionis Pharmaceuticals	USD -228M	99M	2025-12
Nektar Therapeutics	USD -37.05M	15.27M	2024-09
Neurocrine Biosciences	USD 239.4M	52.4M	2025-12
Pfizer	USD 3.33B	290M	2025-09
Prothena	USD -36.91M	44.05M	2025-09
Regeneron Pharmaceuticals	USD 1.76B	244.6M	2025-09
Repligen	USD 17.11M	10.25M	2025-09
Rigel Pharmaceuticals	USD -1.03M	7.22M	2024-06
Sarepta Therapeutics	USD -407.67M	213.63M	2025-12
Teva Pharmaceutical Industries	USD 91M	555M	2025-12
Ultragenyx Pharmaceutical	USD -128M	51.54M	2025-12
Vertex Pharmaceuticals	USD 1.3B	15.8M	2025-09
Xoma	USD 15.98M	24.58M	2024-06

Neurocrine Biosciences Pre Utilidad Fiscal - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2026.